What records are connected here?
- Evidence lanes
- 3
- Source years
- 8
- Drugs@FDA applications
- 1
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved2Evidence: Large human trialsMetabolic and weight · Heart and blood vessels
Also called Tanzeum2
Albiglutide is a GLP-1 receptor agonist made by joining GLP-1 analogue peptides to human albumin, and was the active ingredient in Tanzeum.1,3 FDA approved Tanzeum in 2014, but Drugs@FDA lists it as discontinued.2 In the Harmony Outcomes trial of 9,463 people with type 2 diabetes and cardiovascular disease, it reduced major cardiovascular events compared with placebo (7% versus 9%). Albiglutide is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.3,6
| What it is | A GLP-1 receptor agonist fusion protein, in which GLP-1 analogue peptides are fused to human albumin, recorded by FDA’s substance registry as albiglutide.1 |
|---|---|
| FDA status | FDA-approved, but discontinued. Drugs@FDA lists Tanzeum, application 125431, with an original approval date of April 15, 2014, and lists it as discontinued.2 |
| Human evidence | Harmony Outcomes, a double-blind, randomized, placebo-controlled trial in 9,463 people with type 2 diabetes and cardiovascular disease.3 |
| Evidence strength | Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned |
Albiglutide is a GLP-1 receptor agonist in which copies of a GLP-1 analogue peptide are fused to human albumin, according to FDA’s substance registry.1
In the United States it was the active ingredient of Tanzeum, application 125431, according to Drugs@FDA.2
It activates the GLP-1 receptor. The Harmony Outcomes report notes that GLP-1 receptor agonists differ in chemical structure, duration of action and effects on clinical outcomes.1,3
Harmony Outcomes randomly assigned 9,463 people aged 40 and over with type 2 diabetes and cardiovascular disease to albiglutide or placebo, alongside standard care, and followed them for a median of 1.6 years.3
Cardiovascular death, heart attack or stroke occurred in 338 people (7%) on albiglutide and 428 (9%) on placebo, a hazard ratio of 0.78. Rates of acute pancreatitis, pancreatic cancer and other serious adverse events did not differ between groups.3
Evidence-strength label: Large randomized human trials. How this label is assigned
Yes, but Drugs@FDA lists Tanzeum, application 125431, as discontinued. The application’s original approval date is April 15, 2014.2
FDA’s compounding safety-risk page, current as of April 22, 2026, does not list albiglutide.4
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Albiglutide is not among them.5,6
Why it was discontinued: Drugs@FDA lists its status but the records reviewed here give no reason.2
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Albiglutide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Albiglutide are a bounded selection, not every registration or paper about Albiglutide. For the years before Albiglutide was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Albiglutide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Albiglutide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Tanzeum; discontinued. In the Harmony Outcomes trial of 9,463 people with type 2 diabetes and cardiovascular disease, it reduced major cardiovascular events compared with placebo. Albiglutide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Tanzeum; discontinued. In the Harmony Outcomes trial of 9,463 people with type 2 diabetes and cardiovascular disease, it reduced major cardiovascular events compared with placebo. Albiglutide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date February 1, 2021
Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes.↗Added to PeptideScanner November 16, 2026Regulatory · added November 17, 2026
Federal Register notice 2016-13797↗Source date June 10, 2016Regulatory · added November 17, 2026
Drugs@FDA application BLA125431↗Source date April 15, 2014Literature metadata · added November 16, 2026
Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes.↗Source date February 1, 2021PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
13 of 13 selected trial records include at least one phase value; 13 of 13 include a status value in the retained structured contract.
4 of 4 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
The official Drugs@FDA dataset lists original submission 1 for BLA 125431 with status AP dated 2014-04-15, and names albiglutide among the application record's active ingredients.
The Federal Register published notice 2016-13797, attributed to FDA and its parent HHS department, on 2016-06-10. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; TANZEUM,” and PeptideScanner's exact reviewed identity mapping connects the document to Albiglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00838903 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide.
4 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span April 15, 2014 to February 1, 2021. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 32219329 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, and 1 more PubMed publication type, with publication-date metadata of 2020-06-01 (day precision). PeptideScanner associated the retained record with the identity slug albiglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02229227 at 2026-11-16T17:45:42.793Z. Its registry update date was 2020-11-27, and PeptideScanner's reviewed identity mapping was albiglutide.↗
Literature metadata
PubMed lists PMID 28085780 in The Nurse practitioner as Journal Article, with publication-date metadata of 2017-02-12 (day precision). PeptideScanner associated the retained record with the identity slug albiglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 28409609 in American family physician as Journal Article, Review, with publication-date metadata of 2017-04-15 (day precision). PeptideScanner associated the retained record with the identity slug albiglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00938158 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-07-21, and PeptideScanner's reviewed identity mapping was albiglutide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01077505 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-06-14, and PeptideScanner's reviewed identity mapping was albiglutide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01406262 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-06-08, and PeptideScanner's reviewed identity mapping was albiglutide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01777282 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-05-03, and PeptideScanner's reviewed identity mapping was albiglutide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01098539 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-02-28, and PeptideScanner's reviewed identity mapping was albiglutide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01098461 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-13, and PeptideScanner's reviewed identity mapping was albiglutide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01475734 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-11, and PeptideScanner's reviewed identity mapping was albiglutide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00838903 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
The Lancet · Official source · Source checked November 16, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026